WaveMan
WaveMan · Company
CRL · Charles River Laboratories International, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CRL Charles River Laboratories International (CRL) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Services-commercial physical & biological research · CIK 0001100682
Quote by TradingView
C-suite buying · 1Form 144 · 12
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
14
Codes C/M, not in net · $22.0M priced

What the filings say about CRL

Insiders, 180 days
-$52.1M net sold
1 buyer · 6 sellers · 24% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-05-15
Planned sales (Form 144), 90 days
$35.2M
12 notices

Charles River Laboratories International insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. insiders sold a net $52.1M of stock across 205 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
FOSTER JAMES C
Director
SELL
2026-10-26 SECtraded 2026-10-22
24,042
$8.4M
n/a
Context
  • 56 earlier Form 4 trades (code P or S) here by this insider (2 buys, 54 sales), the last on Aug 25, 2026.
  • +4.9% median (+4.9% mean) 90-day return after 2 previous buys.
  • The trade is 76.1% of the 31,596 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: Director FOSTER JAMES C sold about $8.4M of CRL under a 10b5-1 plan on Oct 22, 2026; 1 other insider sold within 30 days.
Parisotto Shannon M
CEVP, Disc & Safety Assessment
SELL
2026-10-23 SECtraded 2026-10-21
2,156
$742.5K
n/a
Context
  • 25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Oct 5, 2026.
  • The trade is 44.9% of the 4,807 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: CEVP, Disc & Safety Assessment Parisotto Shannon M sold about $742.5K of CRL under a 10b5-1 plan on Oct 21, 2026; 1 other insider sold within 30 days.
Parisotto Shannon M
CEVP, Disc & Safety Assessment
SELL
2026-10-07 SECtraded 2026-10-05
981
$302.6K
+19.9%
Context
  • 24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Aug 19, 2026.
  • The trade is 20.4% of the 4,807 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: CEVP, Disc & Safety Assessment Parisotto Shannon M sold about $302.6K of CRL under a 10b5-1 plan on Oct 5, 2026; 1 other insider sold within 30 days.
Coleman Glenn
EVP & Chief Financial Officer
BUY
2026-10-02 SECtraded 2026-09-30
10
$3.0K
+15.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.0% of the 27,762 shares held after it.
  • No other insider bought within 30 days.
Insider activity: EVP & Chief Financial Officer Coleman Glenn bought about $3.0K of CRL on Sep 30, 2026.
FOSTER JAMES C
Director
SELL
2026-08-27 SECtraded 2026-08-25
33,561
$10.1M
+22.6%
Context
  • 55 earlier Form 4 trades (code P or S) here by this insider (2 buys, 53 sales), the last on Aug 10, 2026.
  • +4.9% median (+4.9% mean) 90-day return after 2 previous buys.
  • The trade is 106.2% of the 31,596 shares held after it.
  • 5 other insiders sold within 30 days.
Insider activity: Director FOSTER JAMES C sold about $10.1M of CRL under a 10b5-1 plan on Aug 25, 2026; 5 other insiders sold within 30 days.
205 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 200 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$52.1M over 180 days
-$35.2M over 90 days
below 94% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-0.9% year over year
below 58% of Pharma & Biotech
Margin
-3.6% net margin
more than 71% of Pharma & Biotech
Buybacks
$323.9M repurchased, FY to 2026-06-27
more than 83% of Pharma & Biotech
Short interest
6.0% of the float short (float per yahoo 2026-10-27) · 2.9 days to cover · settled 2026-10-15
more than 57% of Pharma & Biotech
What changed in the last 30 days
Oct 26Director FOSTER JAMES C sold $8.4M under a 10b5-1 plan (Oct 22)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 23CEVP, Disc & Safety Assessment Parisotto Shannon M sold $1.0M under a 10b5-1 plan (2 trades, Oct 5 to Oct 21)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 22Director FOSTER JAMES C filed to sell $8.4M by Oct 22 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 21Officer Parisotto Shannon M filed to sell $742.5K by Oct 21 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 5Officer Parisotto Shannon M filed to sell $308.6K by Oct 5 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch CRL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+87.1%12M
-21%+15%+51%+87%2025-102025-122026-022026-042026-062026-082026-10 2026-06-29 · FOSTER JAMES C sold $16.9M2026-08-25 · FOSTER JAMES C sold $10.1M2026-10-22 · FOSTER JAMES C sold $8.4M2026-08-10 · FOSTER JAMES C sold $7.9M2026-08-11 · Girshick Birgit sold $1.8M2026-08-05 · Parisotto Shannon M sold $1.3M2026-08-06 · Creamer Victoria L sold $1.1M2026-08-11 · Parisotto Shannon M sold $1.0M2026-10-21 · Parisotto Shannon M sold $742.5K2026-08-19 · Parisotto Shannon M sold $599.7K2026-08-06 · Knell Michael Gunnar sold $330.1K2026-08-06 · Knell Michael Gunnar sold $311.5K2026-10-05 · Parisotto Shannon M sold $302.6K2026-08-06 · Knell Michael Gunnar sold $234.8K2026-08-06 · Knell Michael Gunnar sold $211.8K2026-08-06 · Knell Michael Gunnar sold $190.3K2026-08-06 · Knell Michael Gunnar sold $163.6K2026-08-18 · Andrews Nancy C sold $163.4K2026-08-06 · Knell Michael Gunnar sold $127.8K2026-08-06 · Knell Michael Gunnar sold $104.4K2026-08-06 · Knell Michael Gunnar sold $55.9K2026-03-03 · LaPlume Joseph W bought $4.4K2026-09-30 · Coleman Glenn bought $3.0K2026-10-22 · FOSTER JAMES C filed to sell $8.4M2026-10-21 · Parisotto Shannon M filed to sell $742.5K2026-10-05 · Parisotto Shannon M filed to sell $308.6K2026-08-25 · FOSTER JAMES C filed to sell $10.1M2026-08-19 · Parisotto Shannon M filed to sell $599.7K2026-08-18 · Nancy C Andrews filed to sell $163.3K2026-08-11 · Girshick Birgit filed to sell $1.8M2026-08-11 · Parisotto Shannon M filed to sell $1.0M2026-08-10 · FOSTER JAMES C filed to sell $7.9M2026-08-06 · Michael Knell filed to sell $1.7M2026-08-06 · Victoria Creamer filed to sell $1.1M2026-08-05 · Parisotto Shannon M filed to sell $1.3M2026-06-29 · FOSTER JAMES C filed to sell $16.9M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CRL: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in CRL

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Rob Bresnahan
Sold 2025-05-15 · disclosed 16 days later
$1,001 - $15,000
Jefferson Shreve
Sold 2025-05-12 · disclosed 41 days later
$15,001 - $50,000
Jefferson Shreve
Bought 2025-05-08 · disclosed 45 days later
$15,001 - $50,000
Rob Bresnahan
Bought 2025-04-08 · disclosed 30 days later
$15,001 - $50,000
Julie Johnson
Bought 2025-01-15 · disclosed 28 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CRL planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
FOSTER JAMES C
Filed 2026-10-22
$8.4M
Parisotto Shannon M
Filed 2026-10-21
$742.5K
Parisotto Shannon M
Filed 2026-10-05
$308.6K
FOSTER JAMES C
Filed 2026-08-25
$10.1M
Parisotto Shannon M
Filed 2026-08-19
$599.7K
Government contracts
Award ceilings over the contract's life, subsidiaries included. Not annual revenue (USASpending.gov).
Department Of Health And Human Services
IGF::OT::IGF MANAGEMENT, OPERATION, PROFESSIONAL, AND TECHNICAL SUPPORT SERVICES FOR NIAID ANIMAL C · 2018-04-13
$112.0M
Department Of Health And Human Services
IGF::OT::IGF PATHOLOGY PEER REVIEW&PATHOLOGY SUPPORT FOR DNTP&DIR AT NIEHS; CHARLES RIVER LABORATORI · 2015-08-24
$22.7M
Department Of Health And Human Services
IGF::OT::IGF BREED AND MAINTAIN FREE-RANGING MACACA MULATTA (RHESUS) MONKEYS · 2018-03-27
$16.0M
Department Of Health And Human Services
TASK ORDER SOLICITATION NUMBER: LARC-2025-NIA-0018, TITLED "ANIMAL CARE SERVICES FOR THE NATIONAL IN · 2019-08-12
$9.8M
Department Of Health And Human Services
LINE ITEM #1:PNRC BUILDING 35 ANIMAL CARE - TIME AND MATERIALS · 2019-08-12
$3.4M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Charles River Laboratories International Inc Pac
Cycle 2026 · $0K spent
-
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Ms. Pease
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$14.1M
$18.9M
$3.7M
+56%
+43%
2022
$13.4M
-$11.5M
$3.3M
+43%
+40%
2021
$13.7M
$43.2M
$4.4M
+143%
+41%
2020
$13.5M
$50.0M
$2.8M
+66%
+11%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $52.1M sold by insiders over 180 days, $35.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CRL financials

Revenue growth
-0.9%
XBRL, annual
Net margin
-3.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.0B
four quarters, 2025-06-29 to 2026-06-27
Net margin, TTM
-6.0%
net income over revenue, 2025-06-29 to 2026-06-27
Free cash flow, TTM
$370.6M
operating cash flow minus capex, 2025-06-29 to 2026-06-27
Debt to equity
0.92x
long-term 2026-06-27 plus current 2026-06-27; equity 2026-06-27
Cash flow to debt
0.22x
TTM operating cash flow over long-term 2026-06-27 plus current 2026-06-27
Return on equity
-7.7%
TTM net income over average of 2025-06-28 and 2026-06-27
Return on assets
-3.2%
TTM net income over average of 2025-06-28 and 2026-06-27
Return on invested capital
+1.3%
operating income after a 17.3% effective tax rate, over long-term 2026-06-27 plus current 2026-06-27 plus average of 2025-06-28 and 2026-06-27 minus cash
Return on capital employed
+1.4%
operating income (EBIT proxy) over average of 2025-06-28 and 2026-06-27 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$19.5B
market value at close 2026-10-26 on 2026-07-25 shares, plus long-term 2026-06-27 plus current 2026-06-27, minus cash 2026-06-27
FCF yield
+2.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$4.0B$4.0B$4.1B$4.0B
Operating income$25.2M$227.3M$617.3M$651.0M
Net income-$144.3M$22.2M$474.6M$486.2M
EPS (diluted)-2.910.209.229.48
Operating cash flow$737.6M$734.6M$683.9M$619.6M
Cash$213.8M$194.6M$276.8M$233.9M
Long-term debt$2.1B$2.2B$2.6B$2.7B
Buybacks$360.7M$119.2M$24.2M$38.7M
SEC XBRL, fiscal years, as known on 2026-10-28

CRL Stock Sonar score 6/7 axes

Find similar shapesCompare

CRL ranks highest on profitability (62nd percentile) and institutional and government (58th), and lowest on insider conviction (31st), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
62
Inputs
  • Return on equity-7.7% · 77 pct, sector of 545
  • Return on assets-3.2% · 80 pct, sector of 691
  • Return on invested capital+1.3% · 5 pct, sector of 45
  • Return on capital employed+1.4% · 86 pct, sector of 576
Financial health
51
Inputs
  • Debt to equity0.92x · 21 pct, sector of 352
  • Cash flow to debt0.22x · 82 pct, sector of 371
Growth
46
Inputs
  • Revenue growth, YoY-0.9% · 42 pct, sector of 505
  • Backlog growth, YoY-3.8% · 49 pct, sector of 40
Insider conviction
31
Inputs
  • Net Form 4 buying (codes P and S), 180d-$31.9M · 6 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
58
Inputs
  • Funds adding, latest quarterfewer than five funds report holding it
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$320K · 58 pct, sector of 133
Risk and compliance
39
Inputs
  • Short interest, % of float+6.1% · 54 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+16.6% · 25 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CRL filings, in plain words

Are Charles River Laboratories International insiders buying or selling CRL?

In the 180 days to 2026-10-28, Charles River Laboratories International insiders were net sellers, a net $52.1M: $3.0K of purchases and $52.1M of sales reported on Form 4, by 1 buyer and 6 sellers.

Have members of Congress traded CRL?

Yes, but not in the year to 2026-10-28; the latest on record is a sale by Rob Bresnahan dated 2025-05-15.

Are there planned insider sales of CRL?

Yes. 12 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $35.2M of stock; the latest, by FOSTER JAMES C, was filed 2026-10-22.

Read the full summary

In the 180 days to 2026-10-28, Charles River Laboratories International insiders were net sellers of CRL, a net $52.1M across purchases and sales reported on Form 4 by 1 buyer and 6 sellers. Sales outweighed purchases more than tenfold by value. 24% of the 21 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Members of Congress have disclosed trades in CRL, none in the last year; the latest on record is a sale by Rob Bresnahan dated 2025-05-15. Insiders filed 12 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $35.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies